Scott Patterson, Bruce Johnson, Paul Waring

Transgenomic has established a clinical-commercial advisory board to help guide the development of its ICE COLD-PCR technology for oncology applications. The board is headed by Scott Patterson, vice president of biomarker sciences at Gilead Sciences. Also joining the board are Bruce Johnson, chief clinical research officer at the Dana-Farber Cancer Institute and Harvard Medical School professor, and Paul Waring, director of the Center for Translational Pathology at the University of Melbourne.